Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB XXXX .

@entity1 @entity1149 @entity1295 @entity1277
UNASSIGNED: For @entity1149 ( @entity1149 ) @entity1 at stage IB, adjuvant chemotherapy does not improve survival. Evidence suggests that dendritic cell (DC)-activated cytokine-induced killer (DC-CIK) cell therapy in addition to chemotherapy improves survival for stage I-IIIA @entity1149 @entity1 after surgery, but there are not enough data to confirm this benefit specifically for those at stage IB. Herein, we retrospectively evaluated the efficacy and safety of this therapy administered to stage IB @entity1149 @entity1 . Sixty-six @entity1 were treated with four-cycle adjuvant chemotherapy initiated 3 weeks after surgical resection. In addition, 28 of these @entity1 underwent DC-CIK therapy on a trimonthly basis (average 3.1 times, range 1-6) beginning 1 month after chemotherapy. The disease-free survival (DFS) rates of the two groups were statistically similar, although @entity1 who received DC-CIK therapy showed slightly higher 1- and 2-year DFS rates (100.0% and 96.4%, respectively, compared with 81.6% and 76.3%). More importantly, @entity1 in the DC-CIK therapy group had significantly longer overall survival (p   =   0.018). For @entity1 who received treatment after recurrence, the DC-CIK therapy group had longer progression-free survival compared with the chemotherapy-only group. In addition, @entity1 given DC-CIK therapy experienced less @entity1295 and @entity1277 . The rate of adverse side effects was similar between the two groups. In conclusion, for these stage IB @entity1149 @entity1 , DC-CIK therapy significantly improved 2-year DFS rates compared with those who received chemotherapy only. DC-CIK therapy also benefited @entity1 ' quality of life, and adverse events were acceptable.
